10 mg bulevirtide with PegIFN outperformed bulevirtide alone in treating chronic hepatitis D virus, achieving 46% undetectable HDV RNA levels at 24 weeks.

A Phase IIb trial found that bulevirtide combined with pegylated interferon alfa-2a (PegIFN) outperformed bulevirtide alone in treating chronic hepatitis D virus (HDV). Among patients who received 10 mg of bulevirtide with PegIFN, 46% achieved undetectable HDV RNA levels at 24 weeks after treatment, compared to 12% of those who received 10 mg bulevirtide alone (P<0 .001). < span> This combination therapy may hold potential for severe viral hepatitis.

Articles

MedPage Today

HCPLive

European Pharmaceutical Review

-- show less --